纳武利尤单抗治疗转移性DNA错配修复缺陷或微卫星高度不稳定结直肠癌(CheckMate 142):一项开放标签、多中心、2期研究
这项正在进行中的多中心开放标签2期研究纳入74例经治的dMMR/MSI-H转移性结直肠癌患者,给予纳武利尤单抗3 mg/kg每2周一次。中位随访12.0个月时,23例(31.1%,95% CI 20.8-42.9)获得研究者评估的客观缓解,51例(69%,57-79)疾病控制≥12周;最常见的3/4级药物相关不良事件为脂肪酶升高(6例[8%])和淀粉酶升高(2例[3%])。
要点
- 经治dMMR/MSI-H转移性结直肠癌中,纳武利尤单抗客观缓解率为31.1%(95% CI 20.8-42.9)。
- 疾病控制≥12周者占69%(95% CI 57-79),中位缓解持续时间尚未达到。
- 最常见的3/4级药物相关不良事件为脂肪酶升高(6例[8%])和淀粉酶升高(2例[3%])。
核心结论
- 纳武利尤单抗在经治dMMR/MSI-H转移性结直肠癌患者中提供了持久的缓解和疾病控制,可能成为这些患者的新治疗选择。
研究设计与样本
- 这项正在进行中的多中心、开放标签、2期试验从8个国家(澳大利亚、比利时、加拿大、法国、爱尔兰、意大利、西班牙和美国)的31个站点(学术中心和医院)纳入年龄≥18岁、组织学确诊的复发或转移性结直肠癌患者,经局部评估为dMMR/MSI-H。
- 患者既往至少接受过一线治疗(包括氟嘧啶和奥沙利铂或伊立替康)后进展或不耐受,给予纳武利尤单抗3 mg/kg每2周一次,直至疾病进展、死亡、不可接受的毒性反应或退出研究。
- 主要终点为研究者根据实体瘤疗效评价标准(版本1.1)评估的客观缓解;所有接受至少一剂研究药物的患者均纳入所有分析;试验注册号ClinicalTrials.gov NCT02060188。
主要发现
- 2014年3月12日至2016年3月16日共入组74例患者,其中40例(54%)既往接受过三线或以上治疗。
- 中位随访12.0个月(IQR 8.6-18.0)时,74例中23例(31.1%,95% CI 20.8-42.9)达到研究者评估的客观缓解,51例(69%,95% CI 57-79)疾病控制≥12周。
- 中位缓解持续时间尚未达到;所有缓解者均存活,8例缓解持续≥12个月(Kaplan-Meier 12个月估计值86%,95% CI 62-95)。
- 最常见的3/4级药物相关不良事件为脂肪酶升高(6例[8%])和淀粉酶升高(2例[3%])。
- 研究期间23例(31%)患者死亡,研究者认为无一例与治疗相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer. METHODS: In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188. FINDINGS: Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator. INTERPRETATION: Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients. FUNDING: Bristol-Myers Squibb.
引用
- Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017. PMID: 28734759. doi:10.1016/S1470-2045(17)30422-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。